Rory B. Riggs is Director at Royalty Pharma plc (RPRX). They have made 28 open-market trades across 4 companies since 2002, most recently 2026-01-29.
CIK 0001016835
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
5 open-market purchases totalling $12.6M since 2014, against 23 sales. Across 5 scored buys the stock is down 2.5% at ninety days, and 7.2 points behind the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 20% | 40% | 60% |
| Avg Move | -3.5% | -10.4% | -2.5% |
| Alpha | -3.3% | -11.9% | -7.2% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ITCI | SELL | 2024-06-24 | 2024-06-25 | $75.57 | $674K | -0.1% | +12.8% | +5.8% |
| RPRX | SELL | 2024-01-02 | 2024-01-04 | $28.01 | $19.7M | +2.6% | +0.4% | +4.3% |
| CBUS | BUY | 2023-12-12 | 2023-12-14 | $10.58 | $10.9M | +42.0% | +17.0% | +29.4% |
| CBUS | BUY | 2023-06-01 | 2023-06-02 | $31.50 | $32K | -23.5% | -53.0% | -30.9% |
| RPRX | SELL | 2023-05-22 | 2023-05-22 | $32.82 | $57.4M | +0.6% | -6.7% | -10.7% |
| RPRX | SELL | 2023-03-29 | 2023-03-30 | $36.31 | $10.2M | -0.5% | -2.6% | -18.4% |
| RPRX | SELL | 2022-11-17 | 2022-11-21 | $42.33 | $5.1M | +2.0% | -7.9% | -13.3% |
| RPRX | SELL | 2022-09-14 | 2022-09-15 | $42.31 | $8.5M | -3.7% | +0.0% | -0.8% |
| RPRX | SELL | 2022-08-09 | 2022-08-11 | $43.73 | $3.9M | -0.6% | -0.1% | -1.5% |
| RPRX | SELL | 2022-06-29 | 2022-06-29 | $42.17 | $1.3M | +2.1% | +4.3% | -3.5% |
| RPRX | SELL | 2022-05-19 | 2022-05-23 | $39.42 | $11.8M | +2.5% | +0.8% | +10.3% |
| RPRX | SELL | 2022-03-29 | 2022-03-30 | $38.59 | $2.3M | +6.4% | +9.2% | +9.1% |
| RPRX | SELL | 2022-03-18 | 2022-03-21 | $39.43 | $13.3M | -0.2% | +13.3% | +2.8% |
| ITCI | SELL | 2022-03-16 | 2022-03-18 | $60.11 | $27.2M | -0.4% | +0.0% | -11.8% |
| RPRX | SELL | 2021-12-28 | 2021-12-30 | $40.16 | $11.8M | +4.2% | +0.2% | -2.4% |
| RPRX | SELL | 2021-11-16 | 2021-11-18 | $42.34 | $18.2M | -7.7% | -8.5% | -3.6% |
| RPRX | SELL | 2021-09-28 | 2021-09-30 | $36.44 | $6.7M | -0.5% | +9.6% | +10.2% |
| RPRX | SELL | 2021-06-25 | 2021-06-29 | $42.25 | $83.2M | +1.8% | -6.7% | -9.4% |
| RPRX | SELL · Routine | 2021-06-07 | 2021-06-08 | $45.26 | $12.4M | -5.4% | -11.1% | -16.2% |
| RPRX | SELL | 2020-10-20 | 2020-10-23 | $42.00 | $19.5M | +3.3% | +3.1% | +29.3% |
| RPRX | BUY | 2020-06-18 | 2020-06-23 | $28.00 | $420K | -10.2% | -16.5% | -21.0% |
| FGEN | SELL | 2018-03-12 | 2018-03-14 | $54.66 | $3.5M | -8.6% | -10.0% | +9.1% |
| FGEN | SELL | 2018-03-09 | 2018-03-09 | $55.75 | $2.6M | -8.4% | -17.0% | +0.1% |
| FGEN | SELL | 2017-09-13 | 2017-09-15 | $51.92 | $1.3M | -1.1% | +3.7% | -20.2% |
| FGEN | SELL | 2016-12-16 | 2016-12-16 | $20.87 | $417K | +5.6% | +14.8% | +21.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.